Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 2:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 18,752 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase I Clear all

Conditions: Solid Tumors
Interventions: ARQ 761, ARQ 761 Weekly Administration, Bi-Weekly Administration of ARQ 761, Two Consecutive Weeks Administration of ARQ 761 with one week of rest; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: LAVA-1207, LAVA-1207 plus Pembrolizumab; Biological
Lead sponsor: Lava Therapeutics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: San Francisco, California • Minneapolis, Minnesota • St Louis, Missouri + 3 more

Conditions: Advanced Cancer
Interventions: Ipilimumab, BMS-986218, Nivolumab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 9
States / cities: Atlanta, Georgia • Boston, Massachusetts • Hackensack, New Jersey + 5 more

Conditions: Neurofibromatoses
Interventions: Part 1 Levulan injection, Part 1 Levulan surface application, Part 1 Levulan surface application twice, Part 1 Levulan surface application twice with microneedling, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3; Drug
Lead sponsor: Harry T Whelan, MD; Other
Eligibility: 18 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Lymphoma, Malignant, Hodgkin's Lymphoma, B Cell Lymphoma
Interventions: SB1518; Drug
Lead sponsor: S*BIO; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neuroendocrine Tumor
Interventions: AlphaMedix; Drug
Lead sponsor: Orano Med LLC; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Meningitis, Cryptococcal, HIV Infections
Interventions: Lobradimil, Amphotericin B; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 11
States / cities: Los Angeles, California • Orange, California • San Diego, California + 8 more

Conditions: Celiac Disease
Interventions: 4 dose levels of ALV003; Drug
Lead sponsor: Alvine Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasm, Metastatic Liver Cancer
Interventions: ET140202 autologous T cell product; Biological
Lead sponsor: Eureka Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Duarte, California • Irvine, California • Sacramento, California

Conditions: Postmenopausal Women With Osteoporosis
Interventions: GP2411, EU-Prolia (EU-authorized Prolia®); Biological
Lead sponsor: Sandoz; Industry
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Peoria, Arizona • Miami, Florida • Wichita, Kansas + 3 more

Conditions: Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma
Interventions: ALE.P03; Drug
Lead sponsor: Alentis Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 9
States / cities: Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 6 more

Conditions: Lung Diseases, Cancer
Interventions: Combination Treatment - Cohort 1, Combination Treatment - Cohort 2, Combination Treatment - Cohort 3, Combination Treatment - Cohort 4; Drug
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: filgrastim, carboplatin, paclitaxel, topotecan hydrochloride; Biological · Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2003
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Leukemia
Interventions: Palifermin, Total Body irradiation, Chemotherapy; Drug · Radiation
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 1 Year to 16 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 7
States / cities: Tucson, Arizona • Loma Linda, California • Los Angeles, California + 3 more

Conditions: Type 2 Diabetes Mellitus
Interventions: XW014, Placebo; Drug
Lead sponsor: Sciwind Biosciences USA Co., Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah

Conditions: Healthy
Interventions: MEDI-559, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 1 Month to 23 Months
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 75
States / cities: Greenville, Alabama • Huntsville, Alabama • Mobile, Alabama + 62 more

Conditions: Cutaneous Melanoma, Stage II, Cutaneous Melanoma, Acral Melanoma
Interventions: Wide Local Excision; Diagnostic Test
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Obesity
Interventions: LY3437943, Placebo; Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Orlando, Florida • Baton Rouge, Louisiana • New York, New York

Conditions: Intermittent Claudication
Interventions: Trans sodium crocetinate (TSC), 0.9% normal saline; Drug
Lead sponsor: Diffusion Pharmaceuticals Inc; Industry
Eligibility: 40 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 7
States / cities: Birmingham, Alabama • Santa Rosa, California • Stanford, California + 4 more

Conditions: Malignant Solid Tumor, Lymphomas, Multiple Myeloma
Interventions: AV-299, AV-299 + erlotinib; Biological
Lead sponsor: AVEO Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 3
States / cities: Scottsdale, Arizona • Columbus, Ohio • San Antonio, Texas

Conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: Lonsurf, Gemcitabine, Nab-Paclitaxel; Drug
Lead sponsor: Patrick Joseph Loehrer Sr.; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8
Interventions: Balstilimab, Bevacizumab, Biospecimen Collection, Botensilimab, Computed Tomography, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography, X-Ray Imaging; Biological · Procedure · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Medical Oncology
Interventions: BAY 94-9343, Pemetrexed, Cisplatin; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: Chicago, Illinois • Bethesda, Maryland • Detroit, Michigan + 1 more

Conditions: Healthy Subjects
Interventions: fosamprenavir + ritonavir + methadone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2005
U.S. locations: 2
States / cities: Baltimore, Maryland • Buffalo, New York

Search by objective public record fields.

Clinical Trial of ARQ 761 in Advanced Solid Tumors

Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer

First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors

Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)

A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies

Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET

The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal Meningitis

A Phase 1, Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease

Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma

Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

Combination Paclitaxel, Carboplatin and Temozolomide

Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma

A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT

XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to <24 Month-Old Children

Trial Comparing CPDMA Versus Standard Breadloafing in WLE Specimens of Stage 1-II Cutaneous Melanoma

A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943

Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication

A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma

Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors

Co-Administration Of Fosamprenavir With Methadone: A Drug Interaction Study.